FNIP1: When Human Genetics Points to a New Metabolic Therapy

Article

Nature Already Ran the Experiment: The FNIP1 Story A new August 2006 Nature study,“FNIP1 variants are associated with favourable metabolism in 1 million humans”, illustrates an increasingly powerful approach to drug discovery: find people in whom nature has already altered a biological pathway, understand the resulting advantage, and ask whether a drug can reproduce it. Researchers analyzing genetic data from more than one million people identified rare protein-altering variants in FNIP1-associated with favorable metabolic characteristics. FNIP1 participates in cellular energy and nutrient sensing, making the finding particularly interesting as a potential therapeutic target. The precedent is PCSK9. People with naturally occurring loss-of-function variants in PCSK9 were found to have very low LDL cholesterol and reduced cardiovascular risk. That human genetic experiment helped validate PCSK9 as a therapeutic target and ultimately contributed to an entirely new class of cholesterol-lowering drugs. Could FNIP1 follow a similar path? Experimental work accompanying the human genetics suggests that reducing FNIP1 activity can alter energy expenditure and improve aspects of metabolic function. There is no FNIP1 drug yet, and the approach has not reached clinical trials. Important questions about mechanism, tissue specificity and safety remain. But that's what makes the discovery compelling. Traditional drug development often begins with a target and eventually asks whether manipulating it helps humans. Population-scale genomics allows us to sometimes reverse that process: Human genetic variant → protective phenotype → mechanism → therapeutic target → drug. FNIP1 may or may not ultimately become a successful medicine. But the larger lesson is already clear. Instead of guessing which biological pathways might protect us from disease, we can increasingly find people in whom nature has already performed the experiment. PCSK9 showed where that strategy can lead. FNIP1 may be another experiment worth watching.